(Q44635070)

4 December 2017

p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease (English)

1 reference

4 December 2017

0 references

3

Stefan Rutkowski

1 reference

4 December 2017

1

Marco Gessi

1 reference

4 December 2017

André O von Bueren

2

1 reference

PubMed ID

21796446

4 December 2017

Torsten Pietsch

series ordinal

4

1 reference

4 December 2017

28 July 2011

1 reference

Journal of Neuro-Oncology

4 December 2017

1 reference

4 December 2017

106

1 reference

4 December 2017

1

1 reference

4 December 2017

135-141

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0648-8

4 December 2017

0 references

cites work

Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Medulloblastoma: present concepts of stratification into risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

p53 and disease: when the guardian angel fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

p53 family members in cancer diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

A clinicobiological model predicting survival in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

TP53 alterations and clinical outcome in low grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Clinical outcomes and correlates of TP53 mutations and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Genetically engineered mouse models of brain cancer and the promise of preclinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0648-8

Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

21 January 2018

1 reference

12 December 2020

p53 status and the efficacy of cancer therapy in vivo

1 reference

12 December 2020

p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.

1 reference

12 December 2020

A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes.

1 reference

12 December 2020

10.1007/S11060-011-0648-8

Identifiers

DOI

1 reference

4 December 2017

1 reference

PubMed ID

21796446